Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

315
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
315
Hazard Rate01:11

Hazard Rate

227
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
227
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

330
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
330
Relative Risk01:12

Relative Risk

600
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
600
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

361
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
361
Odds Ratio01:09

Odds Ratio

443
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
443

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

European heart journal·2026
Same author

Hypertension and heart failure: Navigating blood pressure targets and medication titration and tolerance.

Clinical medicine (London, England)·2026
Same author

Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.

Journal of the American Heart Association·2026
Same author

Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.

European heart journal·2026
Same author

Pre-exposure immunohematologic features of heart failure associate with COVID-19 mortality.

NPJ cardiovascular health·2026
Same author

Improving 10-year cardiovascular risk prediction in patients with established cardiovascular disease: flexible addition of risk predictors on top of the SMART2 risk score.

European journal of preventive cardiology·2026
Same journal

Methodological considerations in estimating the burden of congenital heart disease among Indian children.

Indian journal of thoracic and cardiovascular surgery·2026
Same journal

Cardiac transplantation in situs inversus post-TAPVC repair.

Indian journal of thoracic and cardiovascular surgery·2026
Same journal

Size compatibility in pediatric heart transplantation: impact on outcomes.

Indian journal of thoracic and cardiovascular surgery·2026
Same journal

Pulmonary NUT carcinoma mimicking small cell lung cancer: a diagnostic pitfall in high-grade thoracic tumors.

Indian journal of thoracic and cardiovascular surgery·2026
Same journal

Burden of congenital heart disease among Indian children: a systematic review and meta analysis.

Indian journal of thoracic and cardiovascular surgery·2026
Same journal

Outcomes of coronary artery bypass grafting: insights from a single centre in South India.

Indian journal of thoracic and cardiovascular surgery·2026
See all related articles

Related Experiment Video

Updated: Oct 30, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K

Model-free estimates that complement information obtained from the hazard ratio.

Salil Vasudeo Deo1,2, Vaishali Salil Deo1, Varun Sundaram1,2

  • 1Louis Stokes VA Medical Center, Northeast Ohio Veteran Affairs Healthcare System, Cleveland, OH USA.

Indian Journal of Thoracic and Cardiovascular Surgery
|July 5, 2021
PubMed
Summary
This summary is machine-generated.

This study explores the limitations of survival data modeling, particularly the Cox proportional hazards model. It introduces model-free survival estimates like restricted mean survival time and restricted mean lost time, demonstrating their calculation using R or STATA.

Keywords:
BiostatisticsKaplan and Meier methodMedian survival timeRestricted mean survival timeSurvival analysis

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K

Related Experiment Videos

Last Updated: Oct 30, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.4K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.8K

Area of Science:

  • Biostatistics
  • Survival Analysis

Background:

  • The Cox proportional hazards model is widely used but has limitations in survival data modeling.
  • Supplementary materials are available online.

Purpose of the Study:

  • To understand the limitations of survival data modeling, specifically the Cox proportional hazards model.
  • To introduce model-free survival estimates: restricted mean survival time (RMST) and restricted mean lost time (RMLT).

Main Methods:

  • Discusses the limitations inherent in survival data modeling.
  • Introduces RMST and RMLT as model-free alternatives.
  • Demonstrates the use of R and STATA for calculating these survival parameters.

Main Results:

  • Highlights the constraints of the Cox proportional hazards model.
  • Presents RMST and RMLT as valuable, model-free survival metrics.
  • Provides practical guidance for implementing these calculations in statistical software.

Conclusions:

  • Emphasizes the importance of understanding survival modeling limitations.
  • Advocates for the use of RMST and RMLT for robust survival data analysis.
  • Encourages the application of R and STATA for these advanced statistical techniques.